PARLEKARV 250 mg/25 mg, scored tablet 100 tablets
Active ingredients: (S)-(−)-carbidopa, CARBIDOPA MONOHYDRATÉE, LÉVODOPA
Commercialized according to BDPMDispensing in France: Prescription only
Scored tablet100 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PARLEKARV 250 mg/25 mg, comprimé sécable
- Pharmaceutical form
- comprimé sécable
- Route of administration
- orale
- Presentation description
- 1 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 100 comprimés
- Marketing authorisation holder
- ORION CORPORATION
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Jul 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67516522CIP73029516CIP133400930295168Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVODOPAcomprimé | 250,00 mg · un comprimé | SA |
| CARBIDOPA ANHYDREcomprimé | 25,00 mg · un comprimé | FT |
| CARBIDOPA MONOHYDRATÉEcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.